Pfizer Torcetrapib Phase III Program Will Cost $800 Mil.
Executive Summary
Pfizer is spending $800 mil. on the Phase III development program for the cholesterol agent torcetrapib, Worldwide Development President Joe Feczko, MD, said during a Nov. 30 analysts meeting in Groton, Conn
You may also be interested in...
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program
Pfizer’s Torcetrapib/Lipitor Raises HDL Cholesterol, But Blood Pressure Too
Apparent increases in systolic blood pressure caused by Pfizer's torcetrapib/Lipitor (atorvastatin) combination will be investigated in further clinical studies, the firm said